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Abstract
Aims/hypothesis The aim of the present study was to
investigate resource utilisation and associated costs in
patients with diabetic foot ulcers and to analyse differences
in resource utilisation between individuals with or without
peripheral arterial disease (PAD) and/or infection.
Methods Data on resource utilisation were collected pro-
spectively in a European multicentre study. Data on 1,088
patients were available for the analysis of resource use, and
data on 821 patients were included in the costing analysis.
Costs were calculated for each patient by multiplying the
country-specific direct and indirect unit costs by the
number of resources used from inclusion into the study up
to a defined endpoint. Country-specific costs were con-
verted into purchasing power standards.
Results Resource use and costs varied between outcome
groups and between disease severity groups. The highest
costs per patient were for hospitalisation, antibiotics,
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amputations and other surgery. All types of resource
utilisation and costs increased with the severity of disease.
The total cost per patient was more than four times higher
for patients with infection and PAD at inclusion than for
patients in the least severe group, who had neither.
Conclusions/interpretation Important differences in re-
source use and costs were found between different patient
groups. The costs are highest for individuals with both
peripheral arterial disease and infection, and these are
mainly related to substantial costs for hospitalisation. In
view of the magnitude of the costs associated with in-
hospital stay, reducing the number and duration of hospital
admissions seems an attractive option to decrease costs in
diabetic foot disease.
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Abbreviations
Eurodiale European Study Group on Diabetes and the
Lower Extremity
LEA lower extremity amputation
PAD peripheral arterial disease
Introduction
Diabetic foot disease is a common complication of both type
1 and type 2 diabetes. The impact of diabetic foot disease is
substantial; patients with diabetes developing foot ulcers
have a low quality of life and treatment is often long and
intensive [1]. In view of the increasing number of diabetic
patients and limited healthcare resources, data on the cost of
treatment are necessary to prioritise healthcare expenditures
and to attempt to determine which patients and aspects of
treatment are the most important determinants of costs.
Although only a minority of foot ulcers will result in a lower
extremity amputation (LEA) [2], these amputations are
associated with the highest costs. Studies from Sweden have
demonstrated that the cost of treatment for a patient who
healed after an amputation were about €29,000–43,000 in
the 1990s, depending on the amputation level and whether or
not the foot ulcer was infected [3–5]. A recent paper on a
prospective Australian study reported that, on average,
inpatient costs for LEA totalled AU$17,089 [6].
Several retrospective single-centre studies, using different
methodologies, have found that costs for foot ulcer treatment
in general are also high [7–10]. The pathophysiology of
diabetic foot disease is complex, and because several factors
may play a role in the development of foot ulcers, the
population of individuals presenting with diabetic foot ulcers
is relatively heterogeneous. For instance, in a recently pub-
lished paper by the European Study Group on Diabetes and
the Lower Extremity (Eurodiale), in which patients were
grouped according to the presence or absence of peripheral
arterial disease (PAD) and/or infection, individuals with both
PAD and infection were older, more often had severe
comorbidity and frequently had larger ulcers at presentation,
most of which were non-plantar [11]. Many of these factors
also predicted non-healing [2], and poor healing is likely to
be associated with high resource utilisation. Because the
characteristics of patients who are treated in different diabetic
foot units may vary, it is important to obtain prospective data
on resource utilisation and associated costs in relation to
specific patient characteristics. To put the cost of treatment
into perspective, outcome data should also be taken into
account.
The Eurodiale Study was a prospective, multicentre, obser-
vational study on patients with a diabetic foot ulcer. The
design, baseline patient characteristics and clinical out-
comes have been published elsewhere [2, 11, 12]. This
project was also designed as a cost of treatment study, and
its aim was to analyse resource utilisation and associated
costs in a large cohort of well-characterised patients with
diabetic foot ulcers and to determine the differences in
resource utilisation between individuals with or without
PAD and/or infection.
Methods
Study design and population
The Eurodiale consortium is a collaborative network of 14
European diabetic foot centres, created to stimulate research
in the field of diabetic foot disease. The design and
rationale of this study have been described in detail
elsewhere [12]. Briefly, between 1 September 2003 and 1
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October 2004, patients presenting with a new foot ulcer at
14 diabetic foot centres in ten European countries enrolled
in the study. A total of 1,232 patients with a new foot ulcer
were enrolled into the study and 1,088 were followed until
endpoint.
Subjects attended follow-up visits on a monthly basis
until an endpoint or study end was reached. The endpoints
were healing of the complete foot, major amputation and
death. Definitions of the baseline characteristics have been
published previously and are based on the Perfusion,
Extent/size, Depth/tissue loss, Infection and Sensation
(PEDIS) classification system [12, 13]. For the costing
analysis, patients were grouped according to disease
severity, as indicated by the presence or absence of PAD
and/or infection (stages of the University of Texas wound
classification system [14]). The main characteristics of all
patients available for evaluation are presented in Table 1.
Informed consent and ethics committee approval
The study was approved by local ethics committees in all
countries and all participants gave written informed consent.
Unit cost data
Costing consists of two elements: measurement of the re-
sources used and the assignment of unit costs. In the
present study the analysis of resource utilisation for the
management of patients with diabetic foot ulcers is based
on the study data for all patients followed up to endpoint
who were available for analysis (n=1,088).
Given the high variability in underlying pathology and
disease severity, only countries with at least 80 patients
available for analysis were included in the cost analysis, to
ensure that the data were reliable and representative. In
addition, countries for which complete information about
unit costs for every type of resource used could not be
provided were excluded from the cost analysis.
For each country, unit cost data were collected from
official pricelists or other national sources. The unit costs
should, as far as possible, reflect the ‘true’ resource
utilisation in each country. Therefore, the unit cost of a
procedure, a drug or a visit to the clinic included the total
cost, irrespective of who was responsible for paying all or
part of the costs. The payer could be the patient, the
hospital, an authority, an insurance company, or a
combination.
The unit costs of all types of resources used in the
management of diabetic foot ulcers were provided by partici-
pating centres from seven (Czech Republic, Denmark, Italy,
the Netherlands, Slovenia, Sweden and the UK) of the ten
participating countries, using a specific unit cost form. In
total, 75% of the patients available for analysis (n=821) were
included in the economic analysis.
The unit cost form was based on the items listed in the
entry and follow-up forms of the Eurodiale Study [12]. It
contained questions about local currency, year of cost data,
unit costs for inpatient and outpatient care, investigations,
interventions, antibiotics, different types of staff, topical
dressings, transport and the income of the general popula-
tion. For each type of resource it was possible to include
additional comments, e.g. if any unit cost referred to a year
different from the majority of the other unit costs. In
addition, the sources of the unit costs were given.
Cost calculation
Costs were calculated individually for each patient accord-
ing to the resource utilisation indicated in the entry and
follow-up forms. For each country, the utilisation of each
type of resource was multiplied by the corresponding unit
cost for the resource in that particular country. Costs were
calculated from the entry date up to the date of the final
visit. Any unrealistic values of resource utilisation have
been checked and if necessary recoded to avoid overesti-
mation of resource use and costs.
Table 1 Patient characteristics at inclusion
Patient characteristics All patients available for evaluation
n=1,088




Ulcer duration at inclusion
<1 week 184 (17)
<3 months 625 (57)
>3 months 269 (25)
Ulcer size at inclusion
<1.0 cm2 403 (37)
1.0–5.0 cm2 561 (52)
>5.0 cm2 117 (11)
Depth of ulcer at inclusion
Superficial ulcer 612 (56)
Deep ulcer 476 (44)
Comorbidity
Heart failure NYHA III–IV 117 (11)
Inability to stand or walk
without help
107 (10)
Neurological disorder 70 (6)
Visual impairment 164 (15)
End-stage renal disease 63 (6)
Number of patients in each category with percentage within
parentheses except for the age variable. Values are presented as n
(%) unless indicated otherwise. Values for every variable were not
available for all evaluated patients
NYHA, New York Heart Association
a Values are presented as mean (range)
1828 Diabetologia (2008) 51:1826–1834
Diagnostic procedures The costs for diagnostic procedures
were calculated by multiplying the number of each type of
procedure performed for a patient by the unit cost of that
procedure. All costs were then added together to give a total
cost per patient for diagnostic procedures.
Off-loading Off-loading costs were calculated by determin-
ing the total number of footwear, insoles, orthoses and casts
prescribed for a patient and multiplying this by the unit cost
for each type of off-loading. All costs were then added
together a give a total cost per patient for off-loading.
Interventional procedures The costs for interventional
procedures were calculated according to the number and
type of procedures that were performed.
Antibiotic therapy The number of treatment days for each
prescription for antibiotics was calculated by subtracting
the start date from the end date of the prescription. The total
number of treatment days per patient for all antimicrobial
drugs were multiplied by the average daily cost for that
specific drug at the centre or country used. For patients
receiving more than one antibiotic drug simultaneously, the
number of treatment days for each drug were added
together and expressed as the total number of daily doses.
Hospitalisation The costs for hospitalisation were calculat-
ed as the number of days the patient spent in hospital
multiplied by the unit cost for an inpatient day at the centre
of admission. The cost of an inpatient day, also referred to
as the ‘the hotel cost’, was defined as the basic cost,
including food, accommodation, administration services,
nursing and other staff costs.
Management by clinical specialists The costs for manage-
ment by different types of clinical specialists were
calculated according to the unit cost for each type of
specialist and the number of consultations. For patients
treated in inpatient care who were admitted for a duration of
1 week or longer between each study visit, a maximum
number of one consultation per type of specialist was
recorded for that period, with the exception of visits to
family doctors and internists outside the hospital.
Topical treatment The costs for topical treatment were
calculated for dressing material, staff who performed
dressing changes and transportation. Staff costs were
calculated for dressing changes performed by healthcare
workers inside or outside the hospital. If the patient or a
relative or a friend performed dressing changes, there were
no staff costs. Material costs were calculated for all
dressing changes and varied according to the type of
dressing used. A specified list of dressings was included
in the case record form; if ‘other’ dressing or ‘not known’
was indicated, the average cost of all other types of
dressings used in that particular centre was used in the
calculations. Transportation costs were calculated based on
the information provided in the study entry form regarding
the distance between the patient’s home and the hospital.
Transportation costs were included for all dressing changes
that were performed by healthcare workers outside or inside
the hospital. Thus, transportation costs are included in the
analysis irrespective of whether it was the patient or a
healthcare worker who travelled.
Indirect costs Indirect costs related to loss of production
were analysed for patients who were employed and had
been on sickness leave because of the foot ulcer. Costs were
calculated by multiplying the number of weeks a patient
had been on sickness leave by the average income per week
of the general population in the country of residence.
Cost conversions and currency All costs are expressed in
Euros (€), according to the prices in 2005. If the unit cost
for a specified resource was not available for 2005, the
unit cost from another year was adjusted to give the price
for 2005 using a country-specific consumer price index.
Information about the consumer price index was collected
from official statistics for each country or from the
European Central Bank. Local currencies were converted
into Euros using the official exchange rates for the end of
2005, obtained from the European Central Bank. In
addition, costs were adjusted to account for differences
in price levels between countries, using a volume index of
gross domestic product (GDP) per capita in purchasing
power standards. The viewpoint or perspective of the
study is societal, i.e. both direct and indirect costs are
considered, irrespective of the source of financing for the
resources.
Statistical analyses Statistical analysis and cost calculations
were performed using the SPSS statistical package, version
12.0.2 (SPSS, Chicago, IL, USA).
Results
Resource utilisation for management of diabetic foot ulcers
Resource utilisation for the different disease severity groups
is shown in Table 2. The disease severity grouping is based
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Table 2 Resource utilisation in relation to ulcer severity score






















55 (22.4) 118 (42.8) 86 (46.0) 199 (68.6) 39 (43.3) 497 (45.7)
Hospital stay
(weeks)








0.10 (0–2) 0.18 (0–2) 0.22 (0–4) 0.40 (0–4) 0.19 (0–3) 0.23 (0–4)
Above the ankle
(lower leg)
0.01 (0–1) 0.00 (0–1) 0.03 (0–1) 0.08 (0–1) 0.02 (0–1) 0.03 (0–1)
Other interventions and surgery












117 (47.8) 191 (69.2) 101 (54.0) 204 (70.3) 49 (54.4) 662 (60.8)
Total number of
daily doses
29.8 (0–619) 43.1 (0–350) 35.4 (0–327) 46.7 (0–361) 36.9 (0–305) 39.21 (0–619)
Off-loading
footweare (pairs)
1.90 (0–11) 2.40 (0–15) 2.29 (0–14) 2.38 (0–12) 2.14 (0–20) 2.24 (0–20)




5.60 (0–36) 7.01 (0–60) 6.50 (0–101) 9.52 (0–106) 7.09 (0–62) 7.28 (0–106)
Wound care
specialistg
1.00 (0–31) 1.36 (0–25) 1.12 (0–36) 1.01 (0–26) 0.49 (0–16) 1.08 (0–36)
Paramedicsh 5.51 (0–69) 7.72 (0–80) 6.72 (0–91) 7.50 (0–106) 12.10 (0–133) 7.35 (0–133)
Sickness leave
(weeks)
1.37 (0–38) 2.38 (0–39) 0.78 (0–43) 0.72 (0–34) 0.74 (0–24) 1.30 (0–43)
Values are presented as average number (range) of procedures per patient, except those for patients treated with inpatient care and antibiotics,
which are presented as n (%)
aOverall there were 71 patients who could not be linked to any of the four types of severity score
bRevascularisation: vascular surgery, percutaneous transluminal angioplasty
cOther interventions and surgery: surgical debridement, plastic surgery, orthopaedic surgery, other surgery
dDiagnostic procedures and interventions: pressure platform, toe pressure, ankle pressure, transcutaneous O2 pressure measurement, duplex
Doppler ultrasound, x-ray, contrast angiography, scintigram, magnetic resonance angiography, magnetic resonance imaging, computed
tomography scan, bone biopsy, microbiology
eOff-loading: temporary footwear, orthopaedic shoes, total contact cast, insoles, orthoses, other casts
fMedical specialist: family doctor, internist working inside or outside hospital, diabetologist, general surgeon, vascular surgeon, orthopaedic
surgeon, plastic surgeon, infectious disease specialist, radiologist, dermatologist, rehabilitation specialist
gWound care specialist: either medical specialist or paramedics, according to local practice
h Paramedics: podiatrist or chiropodist, orthopaedic shoemaker or orthotist, cast technician, diabetic nurse, district nurse or home-care nurse,
dietitian
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on the presence or absence of PAD and/or infection at
baseline, as follows: group A, patients without infection
and PAD; group B, patients with infection but without
PAD; group C, patients with PAD but without infection;
and group D, patients with both infection and PAD. A
number of patients (n=71) could not be placed in any
disease severity score group because of missing data. In
general, the average number of procedures used for diagnosis
and investigations was low. Microbiology was the most
frequently used diagnostic procedure and temporary footwear
and orthopaedic shoes were the most frequently used off-
loading techniques in all groups (data not shown). There were
large differences in resource use between individual patients,
as illustrated by the large ranges shown for many of the
variables. The percentage of patients treated in inpatient care
was relatively high, ranging from 22% of patients in the
group with the least severe disease (group A) to 67% of
patients with both infection and PAD (group D). Not
surprisingly, treatment with antibiotics was most frequent in
the group of patients with infection but without PAD (group
B, 69%) and patients with both infection and PAD (group D,
70%) but was common in all outcome groups. Consultations
with medical specialists and paramedics were also frequent in
all groups.
Costs of diabetic foot ulcers
The total treatment cost per patient in relation to disease
severity is illustrated in Table 3. In all disease severity
groups, the costs of hospitalisation and antibiotics repre-
sented a large part of the total direct costs. In addition, the
average costs of amputation, revascularisation and other
interventions and surgery were high in patients with both
infection and PAD (group D). For patients in the group with
most severe disease (group D), the average total costs were
almost four times as high as those for patients with the least
severe disease (group A). On the other hand, the indirect
costs were higher in the two groups with the least severe
disease (groups A and B) than in those more severe disease
(groups C and D). This can be explained by the greater
frequency of employment among patients with less severe
disease; the employment rate for groups A and B combined
was 39% vs 11% for groups C and D together (p<0.01).
The cost pattern between different types of resources
shown in Table 3 is similar to that observed when costs are
related to the clinical outcome over the 1 year study period
(Table 4). The highest costs in all outcome groups were for
hospitalisation. Other resources with high costs were
surgery, ‘other interventions’ and antibiotics. In patients
Table 3 Resource utilisation in relation to ulcer severity score





















808 (18) 3,703 (40) 4,433 (45) 6,787 (40) 4,599 (40) 3,892 (39)
Amputations 198 (4) 499 (5) 594 (6) 2,411 (14) 687 (6) 889 (9)








74 (2) 111 (1) 190 (2) 260 (2) 225 (2) 160 (2)




435 (10) 448 (5) 447 (5) 503 (3) 445 (4) 457 (5)
Topical treatment 368 (8) 446 (5) 679 (7) 1,057 (6) 1,029 (9) 658 (7)
Consultations/
outpatient visits
448 (10) 707 (8) 549 (6) 687 (4) 1,221 (11) 653 (6)
Total direct costs 3,771 8,113 9,622 16,414 11,120 9,446
Indirect costs 743 (16) 1,160 (13) 229 (2) 421 (3) 335 (3) 645 (6)
Total direct and
indirect cost
4,514 (100) 9,273 (100) 9,851 (100) 16,835 (100) 11,455 (100) 10,091 (100)
The direct and indirect costs per patient with diabetic foot ulcers are presented in Euros (% of total), according to 2005 prices, and have been
weighted by purchasing power standards. Out of the 1,088 patients who were available for evaluation, 821 were included in the costing analysis
aOverall there were 71 patients who could not be linked to any of the four types of severity score
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whose ulcers did not heal within the observation period of
12 months, the costs of topical treatment and consultations
were high, highlighting the influence of treatment duration
for these types of resources. The highest total costs were
found in patients who had undergone major amputations,
and lowest in the group of patients whose ulcer healed. The
costs of diagnostic procedures, investigations, off-loading
and orthopaedic appliances were rather low in all groups,
irrespective of disease severity or outcome (Tables 3 and 4).
Discussion
In this study we have collected prospective data on resource
use and costs associated with the treatment of diabetic foot
ulcers. Costs are high, the average total for direct and
indirect cost being approximately €10,000, based on the
costing data of 821 patients from the participating
countries. Importantly, resource utilisation and costs varied
between the different outcome groups and between indi-
viduals with and without PAD and/or infection at baseline.
The average costs reported in this study cannot easily be
compared with data published in the current literature in
view of the differences with respect to included patients,
duration of follow-up and methods for analyses. The data
may be compared with the single-centre data from Sweden,
reported in the early 1990s, in which costs for primary
healing of the ulcer were approximately US$8,950 [15],
which is about €7,412 according to 2005 prices. The results
reported by an American group, based on medical and
pharmaceutical claims data from 2000 and 2001, included
both in- and outpatients with and without PAD. The
average direct cost per ulcer episode was US$13,179
(approximately €10,914), ranging from US$5,218 (€4,321)
in patients with adequate vascular status to US$23,372
(€19,357) in individuals with inadequate vascular status
[16]. In the present European study, costing data are derived
from several countries, including both low- and high-cost
countries, although costs were weighted by purchasing power
standards to compensate for this. These data very clearly
demonstrate that treatment of diabetic foot disease is a major
determinant of diabetes-related resource utilisation and costs
throughout Europe. Based on the data for Europe for 2003,
which showed a prevalence of diabetes of 48 million people
and an ulcer incidence among diabetic patients of 2% per
year [1], the costs associated with the treatment of diabetic
foot ulcers may be as high as ten billion Euros per year.
It is clear from the present study that the costs for the
treatment of individuals with PAD, especially in combin-
ation with infection, are substantially higher than those for
the treatment of patients without PAD. Only a small
proportion of this difference is attributable to higher costs
for diagnostic procedures. Most of the excess costs in
individuals with PAD and infection are related to a higher
rate of hospitalisation and higher costs of antibiotics,
amputations, revascularisation and other surgery. We have
previously demonstrated that characteristics and predictors
of outcome are very different in patients with and without
PAD, which suggests that these conditions should be
regarded as separate disease states [2]. The resource and
cost data reported here support this concept. Habacher et al.
[7] recently published retrospective data on a group of 89
patients from an Austrian tertiary referral hospital in which
similar differences between patients with and without PAD











Hospitalisation (hotel cost) 2,647 (34) 4,771 (55) 10,953 (43) 8,907 (44)
Amputations 602 (8) 498 (6) 6,907 (27) 718 (4)
Revascularisation 538 (7) 238 (3) 624 (2) 734 (4)
Other interventions and surgery 712 (9) 949 (11) 2,894 (11) 2,042 (10)
Diagnostic procedures and
investigations
126 (2) 104 (1) 289 (1) 345 (2)
Antibiotics 1,060 (14) 959 (11) 1,208 (5) 2,120 (11)
Off-loading/orthopaedic appliances 449 (6) 165 (2) 360 (1) 636 (3)
Topical treatment 473 (6) 470 (5) 922 (4) 1,780 (9)
Consultations/outpatient visits 540 (7) 473 (5) 383 (2) 1,508 (8)
Total direct costs 7,147 8,628 24,540 18,790
Indirect costs 574 (7) 25 (0) 681 (3) 1,275 (6)
Total direct and indirect cost 7,722 (100) 8,653 (100) 25,222 (100) 20,064 (100)
The direct and indirect costs per patient with diabetic foot ulcers are presented in Euros (% of total), according to 2005 prices, and have been
weighted by purchasing power standards. Out of the 1,088 patients who were available for evaluation, 821 were included in the costing analysis
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and/or infection were observed. They reported costs for the
patients with foot ulcers but without PAD and infection of
€1,071 vs €7,844 for the patients with both PAD and infec-
tion. However, the costs for the latter group were less than
50% of those for the corresponding group in our cohort. This
difference may be related to differences in costing between
the studies, for example, it is unclear whether staff costs for
dressing changes in outpatient care were included in the
Austrian study.
In the current study, the majority of costs for the treat-
ment of diabetic foot disease were related to hospital
admissions. In the Eurodiale Study, 27% of the patients
were admitted at baseline [11] and a number of patients
were admitted during follow-up. In view of the magnitude
of these costs, reducing the number and duration of hospital
admissions seems an attractive option for decreasing the
costs associated with the treatment of diabetic foot disease.
The hospital admissions are usually related to progressive
tissue loss in the context of PAD and/or infection. We think
that strategies aimed at early referral, timely institution of
antibiotic therapy and early vascular intervention may help
to prevent progressive tissue loss, thereby reducing admission
rates. The development of such strategies should be one of
the main priorities in diabetic foot care over the next years.
The costs for lower leg amputations in this study are not
completely comparable with those reported by previous
studies. One possible explanation for this is that patients
who underwent a lower leg amputation in the present study
were only followed until this amputation was performed,
whereas in previous Swedish studies, patients were fol-
lowed and costs calculated until the amputated leg was
completely healed [15, 17]. Similarly, the cost of a lower
leg amputation reported by the recent Australian study is
considerably lower than that reported by the present study,
mainly because only inpatient costs were included in their
analyses [6]. Patients included in the present study who
underwent minor amputations below the ankle, which
subsequently healed, were classified as healed patients,
whereas the costs of minor amputations were presented
separately in the previous Swedish studies [15, 17]. The total
average costs for patients classified as healed are therefore
probably higher than if patients who had undergone a minor
amputation had not been included in this group.
In the present study the average costs of antibiotics
constituted between 11% and 14% of the total direct costs for
patients with infection, despite the fact that some antibiotic
use was probably not reported. The number of patients with
infection reported to be treated with antibiotics was
significantly less than 100%. These costs are much higher
than those reported by a Swedish study in which the share of
costs for antibiotics was 4.5% [17]. One reason for this
discrepancy in costs could be the use of more expensive
antibiotics, more parenteral drugs and longer treatment
periods across 2003–2004 compared with the early 1990s.
Moreover, policies for the prescription of antibiotics can
differ substantially between countries, stressing the import-
ance of performing multinational studies.
One limitation of the study is that unit cost data could
not be calculated for all participating countries because of
the lower number of patients enrolled and difficulties in
obtaining data on certain resources in some countries. Cost
calculations were possible for seven of the ten countries or
75% of the patients included. Difficulties in collecting
reliable unit costs have previously been described and
should not be neglected when planning health-economic
studies [18]. These difficulties also indicate the importance
of reporting resource utilisation in terms of physical
quantities (e.g. two dressings, two bypasses). Another
limitation is that the analyses of resource utilisation and
costs do not include the total resources used for the
management of diabetic foot disease because patients could
have been treated for their present foot ulcer at a different
centre before being included in the study. Thus, the actual
values for resource use and costs are probably higher than
reported in this article, but, in general, it is too difficult to
accurately obtain information on treatment retrospectively.
The study is also limited by the fact that recurrent ulcers
were excluded, and that a proportion of the cohort
(although less than a third) were tertiary referrals to
specialised centres, which may treat more complex patients.
Finally, any cost of treatment study is limited by the
incomplete generalisability of economic data or transfer-
ability of results from one country to another [19].
Treatment costs are, amongst other things, influenced by
differences in the availability of healthcare resources and
variations in clinical practice, together with differences in
incentives given to healthcare professionals. As described
elsewhere, we found significant variations in clinical practice
between centres. In particular, there were marked differences
in the use of resources such as total contact casting and
vascular imaging [20]. In addition, the relative prices and
costs may vary between countries. This problem has at least
partly been circumvented in the present study by the
conversion of local costs into purchasing power standards.
Although the current study is subject to several weak-
nesses, as described above, a strength was the relatively
large cohort monitored prospectively in daily clinical
practice until a predefined treatment outcome or study end
date was reached, with no predetermined intervention
options. Ten European countries participated in the resource
use analysis and data from seven countries and ten centres
were available for the cost analysis. The perspective of the
study was societal, including both direct and indirect costs,
irrespective of payers and reimbursement systems in the
participating countries. The present information illustrates
the magnitude of the problem in economic terms for
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decision makers both within and outside the healthcare
system. Moreover, it can help us to define target groups for
whom an improvement in care could result in major savings
in healthcare expenditure. Up to now many publications in
the field of diabetic foot disease have focused on wound
healing in patients with a neuropathic foot ulcer, the group
with the lowest costs in our analyses. Although several
studies on the treatment of infection have been published,
patients with PAD were usually excluded or not specifically
analysed in these studies. Our data suggest that to reduce
the high costs of diabetic foot disease, major efforts should
be undertaken to improve the treatment in this subgroup of
patients, who have the highest costs and the poorest outcome.
This health-economic study is mainly descriptive, but the
database constructed could be a valuable resource for future
health-economic model simulations, allowing the cost-effec-
tiveness of different management strategies to be evaluated.
Such studies may be helpful to achieve a more cost-effective
use of the resources in healthcare and society in general.
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